These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

463 related items for PubMed ID: 26942254

  • 21. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
    Zhao SZ, Burke TA, Whelton A, von Allmen H, Henderson SC.
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S392-400. PubMed ID: 12416789
    [Abstract] [Full Text] [Related]

  • 22. Cardiovascular safety of NSAIDs.
    Harbin M, Turgeon RD, Kolber MR.
    Can Fam Physician; 2014 Mar; 60(3):e166. PubMed ID: 24627399
    [No Abstract] [Full Text] [Related]

  • 23. Does the varied use of NSAIDs explain the differences in the risk of myocardial infarction?
    van Staa TP, Rietbrock S, Setakis E, Leufkens HG.
    J Intern Med; 2008 Nov; 264(5):481-92. PubMed ID: 18624902
    [Abstract] [Full Text] [Related]

  • 24. Lessons from 20 years with COX-2 inhibitors: Importance of dose-response considerations and fair play in comparative trials.
    Stiller CO, Hjemdahl P.
    J Intern Med; 2022 Oct; 292(4):557-574. PubMed ID: 35585779
    [Abstract] [Full Text] [Related]

  • 25. Rofecoxib in rheumatoid arthritis: new indication. No better that other NSAIDS.
    Prescrire Int; 2003 Jun; 12(65):89-90. PubMed ID: 12825570
    [Abstract] [Full Text] [Related]

  • 26. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
    Rahme E, Nedjar H.
    Rheumatology (Oxford); 2007 Mar; 46(3):435-8. PubMed ID: 17255138
    [Abstract] [Full Text] [Related]

  • 27. Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level.
    Varas-Lorenzo C, Maguire A, Castellsague J, Perez-Gutthann S.
    Pharmacoepidemiol Drug Saf; 2007 Apr; 16(4):366-76. PubMed ID: 16897817
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone).
    Reicin AS, Shapiro D, Sperling RS, Barr E, Yu Q.
    Am J Cardiol; 2002 Jan 15; 89(2):204-9. PubMed ID: 11792343
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs.
    Patrono C.
    Curr Cardiol Rep; 2016 Mar 15; 18(3):25. PubMed ID: 26841787
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Cardiovascular risks of continuing vs. initiating NSAIDs after first-time myocardial infarction or heart failure: a nationwide cohort study.
    Schmidt M, Hallas J, Ernst MT, Pottegård A.
    Eur Heart J Cardiovasc Pharmacother; 2023 Sep 20; 9(6):562-569. PubMed ID: 37385823
    [Abstract] [Full Text] [Related]

  • 35. Cardiovascular risks associated with low-dose ibuprofen and diclofenac as used OTC.
    Moore N, Salvo F, Duong M, Blin P, Pariente A.
    Expert Opin Drug Saf; 2014 Feb 20; 13(2):167-79. PubMed ID: 24256349
    [Abstract] [Full Text] [Related]

  • 36. Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study.
    Rahme E, Watson DJ, Kong SX, Toubouti Y, LeLorier J.
    Pharmacoepidemiol Drug Saf; 2007 May 20; 16(5):493-503. PubMed ID: 17086567
    [Abstract] [Full Text] [Related]

  • 37. Valdecoxib is associated with improved dyspepsia-related health compared with nonspecific NSAIDs in patients with osteoarthritis or rheumatoid arthritis.
    Rabeneck L, Goldstein JL, Vu A, Mayne TJ, Rublee DA.
    Am J Gastroenterol; 2005 May 20; 100(5):1043-50. PubMed ID: 15842577
    [Abstract] [Full Text] [Related]

  • 38. [Diclofenac: update on tolerableness and spinal anti-inflammatory action].
    Sandri A.
    Minerva Med; 2014 Aug 20; 105(4):313-8. PubMed ID: 25078485
    [Abstract] [Full Text] [Related]

  • 39. Cardiovascular safety of using non-steroidal anti-inflammatory drugs for gout: a Danish nationwide case-crossover study.
    Bech-Drewes A, Bonnesen K, Hauge EM, Schmidt M.
    Rheumatol Int; 2024 Jun 20; 44(6):1061-1069. PubMed ID: 38581450
    [Abstract] [Full Text] [Related]

  • 40. The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non-steroidal anti-inflammatory drugs.
    van der Linden MW, van der Bij S, Welsing P, Kuipers EJ, Herings RM.
    Ann Rheum Dis; 2009 May 20; 68(5):668-73. PubMed ID: 18495734
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.